Provider Briefing: Cyclobenzaprine Supply in 2026

Cyclobenzaprine remains one of the most frequently prescribed skeletal muscle relaxants in the United States, with tens of millions of prescriptions written annually. In 2026, providers are increasingly hearing from patients who can't fill their Cyclobenzaprine prescriptions — and the reasons extend beyond a simple supply-and-demand mismatch.

This briefing covers the current availability landscape, the factors driving supply disruptions, prescribing considerations, therapeutic alternatives, and tools to help your patients access their medications.

Timeline: How We Got Here

Cyclobenzaprine's availability challenges didn't appear overnight. Here's a brief timeline of the key developments:

• 2012–2013: The brand-name Flexeril was discontinued as the market shifted entirely to generic formulations. Multiple generic manufacturers entered the market.
• 2015–2020: Ongoing consolidation in the generic pharmaceutical industry reduced the number of active Cyclobenzaprine manufacturers. Several mergers and facility closures thinned the supplier base.
• 2021–2023: Global supply chain disruptions — exacerbated by pandemic aftereffects — affected raw material availability for many generic medications, including Cyclobenzaprine.
• 2024–2025: Spot shortages began appearing more frequently, particularly for the 5 mg and 7.5 mg tablet strengths. The FDA did not list Cyclobenzaprine as a formal shortage, but pharmacy-level stock-outs became a regular occurrence.
• 2026 (current): Intermittent supply disruptions continue. The 10 mg immediate-release tablet remains the most consistently available formulation. Extended-release capsules (Amrix) have limited distribution.

Prescribing Implications

The supply situation has several practical implications for prescribers:

Strength Selection

When clinically appropriate, consider prescribing the 10 mg immediate-release tablet, which has the most reliable supply. For patients who require lower doses:

• The 10 mg tablet can be split for an approximate 5 mg dose (immediate-release tablets only — extended-release capsules should never be split or crushed)
• Document the reason for strength selection in your notes to support prior authorization if needed

Duration of Therapy

Cyclobenzaprine is FDA-approved for short-term use (2–3 weeks) as an adjunct to rest and physical therapy. Reinforcing this guideline is especially important during supply constraints — shorter courses mean fewer refill challenges for patients and more equitable distribution of available supply.

Patient Population Considerations

Remind your clinical team of key prescribing considerations:

• Elderly patients (≥65): Cyclobenzaprine is listed on the Beers Criteria as potentially inappropriate for older adults due to anticholinergic burden and sedation risk. Consider Methocarbamol or non-pharmacological approaches first.
• Patients on serotonergic medications: Cyclobenzaprine's structural similarity to tricyclic antidepressants means concomitant use with SSRIs, SNRIs, triptans, or tramadol increases serotonin syndrome risk. Screen medication lists carefully.
• Cardiac patients: Cyclobenzaprine is contraindicated in patients with arrhythmias, heart block, conduction disturbances, heart failure, or in the acute recovery phase of myocardial infarction.
• Hepatic impairment: Cyclobenzaprine is extensively metabolized by the liver. Avoid or use with extreme caution in patients with hepatic impairment.

For a detailed review of interactions, see Cyclobenzaprine Drug Interactions.

Current Availability Picture

Based on reports from pharmacies and distribution data:

• 10 mg IR tablets: Generally available at most pharmacies, though spot shortages occur
• 5 mg IR tablets: Intermittent availability — frequently backordered at chain pharmacies
• 7.5 mg IR tablets: Similar challenges to 5 mg, with fewer manufacturers producing this strength
• 15 mg and 30 mg ER capsules (Amrix): Limited distribution; many pharmacies do not routinely stock these

Independent pharmacies tend to have more reliable access due to diversified distributor relationships. Encourage patients to check availability using Medfinder for Providers before sending them to a specific pharmacy.

Cost and Access Considerations

Cyclobenzaprine remains affordable as a generic medication:

• Insured patients: Tier 1 preferred generic on most formularies; typical copay $0–$15
• Uninsured patients: Cash price approximately $10–$45 for 30 tablets; discount cards (GoodRx, SingleCare) can reduce this to $10–$20
• Patient assistance: NeedyMeds and RxAssist maintain databases of assistance programs for qualifying patients

Cost is generally not the barrier — availability is. When patients report difficulty filling prescriptions, it's almost always a stock issue rather than a price issue.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder offers real-time pharmacy availability data that your clinical team can use to direct patients to pharmacies with Cyclobenzaprine in stock. This can be integrated into your discharge or after-visit workflow to reduce patient callbacks about unfilled prescriptions.

Prescribing Workflow Recommendations

1. Check availability first: Before sending a prescription, use Medfinder to confirm the chosen pharmacy has stock
2. Default to 10 mg when appropriate: This strength has the best supply reliability
3. Include a backup alternative: Consider noting a therapeutic alternative in the patient's chart in case Cyclobenzaprine can't be filled
4. Empower patients: Share resources like how to find Cyclobenzaprine in stock so patients can help themselves
5. Document supply issues: If switching medications due to availability, document the clinical rationale

Therapeutic Alternatives at a Glance

When Cyclobenzaprine is unavailable or inappropriate, consider:

• Methocarbamol (Robaxin): Less sedating, well tolerated, good supply. Preferred for elderly patients or those sensitive to anticholinergic effects.
• Tizanidine (Zanaflex): Alpha-2 agonist mechanism, shorter duration, useful for both spasm and spasticity. Monitor liver function.
• Baclofen: GABA-B agonist, best for neurological spasticity. Must taper — abrupt discontinuation can cause withdrawal.
• Metaxalone (Skelaxin): Least sedating option. Higher cost may be a barrier for uninsured patients.

Looking Ahead

The generic drug supply landscape continues to evolve. While there's no indication that Cyclobenzaprine will face a full national shortage, the intermittent disruptions seen in 2025–2026 may persist as the generic market adjusts to consolidation and supply chain pressures.

Proactive prescribing — including strength flexibility, therapeutic alternatives, and patient education about availability tools — will help your patients maintain access to effective muscle spasm relief.

Final Thoughts

Cyclobenzaprine remains a clinically effective and affordable muscle relaxant, but availability challenges require providers to be more deliberate in their prescribing approach. Favor the 10 mg strength when possible, have alternatives ready, and leverage tools like Medfinder for Providers to reduce friction in the prescription-filling process.

For patient-facing resources you can share, see our Cyclobenzaprine shortage update for patients.